DiaMedica Therapeutics (NASDAQ:DMAC) Trading Down 1.3% – What’s Next?

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC)’s stock price dropped 1.3% during mid-day trading on Tuesday . The company traded as low as $6.71 and last traded at $6.79. Approximately 131,193 shares traded hands during mid-day trading, a decline of 49% from the average daily volume of 256,443 shares. The stock had previously closed at $6.88.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, October 8th. Lake Street Capital upped their price target on shares of DiaMedica Therapeutics from $11.00 to $14.00 and gave the company a “buy” rating in a report on Friday, July 18th. Wall Street Zen upgraded shares of DiaMedica Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 4th. Craig Hallum upped their price target on shares of DiaMedica Therapeutics from $8.00 to $11.00 and gave the company a “buy” rating in a report on Friday, July 18th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of DiaMedica Therapeutics in a report on Friday, August 15th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.33.

DiaMedica Therapeutics Price Performance

The company’s 50 day moving average is $6.62 and its two-hundred day moving average is $5.02. The firm has a market cap of $350.98 million, a P/E ratio of -9.84 and a beta of 1.40.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, meeting the consensus estimate of ($0.18). Research analysts predict that DiaMedica Therapeutics, Inc. will post -0.59 EPS for the current year.

Insider Buying and Selling at DiaMedica Therapeutics

In related news, major shareholder Jan Stahlberg bought 50,772 shares of DiaMedica Therapeutics stock in a transaction that occurred on Wednesday, August 27th. The stock was acquired at an average price of $6.00 per share, for a total transaction of $304,632.00. Following the completion of the purchase, the insider owned 7,764,465 shares in the company, valued at approximately $46,586,790. This represents a 0.66% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have bought a total of 1,000,000 shares of company stock valued at $5,958,598 in the last three months. 7.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Police & Firemen s Retirement System of New Jersey bought a new position in DiaMedica Therapeutics during the second quarter worth about $29,000. Bank of America Corp DE lifted its stake in DiaMedica Therapeutics by 3,710.3% during the second quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after purchasing an additional 8,274 shares during the period. JPMorgan Chase & Co. bought a new position in DiaMedica Therapeutics during the second quarter worth about $49,000. Invesco Ltd. bought a new position in DiaMedica Therapeutics during the second quarter worth about $54,000. Finally, Intech Investment Management LLC bought a new position in DiaMedica Therapeutics during the second quarter worth about $56,000. Institutional investors own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.